Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rani Therapeutics Holdings ( (RANI) ) has shared an update.
On October 16, 2025, Rani Therapeutics Holdings, Inc. entered into a securities purchase agreement with certain investors that called for governance changes, including amendments to its organizational documents and the unwinding of select legacy arrangements, signaling a broader realignment of its capital and governance structure. As part of this process, on December 31, 2025, the company and InCube Labs, LLC agreed to terminate a Tax Receivable Agreement dating from August 3, 2021, mutually releasing each other from all obligations without any tax benefit or early termination payments, thereby removing a future liability from Rani’s balance sheet. In a related step, on November 24, 2025, the majority voting stockholder approved, by written consent, the issuance of Class A common shares upon exercise of warrants under the purchase agreement and the adoption of a restated charter, with these actions becoming effective on December 31, 2025, in compliance with Nasdaq rules and Delaware law, further consolidating the company’s governance and capital changes without the need for a stockholders’ meeting.
The most recent analyst rating on (RANI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Rani Therapeutics Holdings stock, see the RANI Stock Forecast page.
Spark’s Take on RANI Stock
According to Spark, TipRanks’ AI Analyst, RANI is a Neutral.
The score is held down primarily by weak financial performance (minimal/flat revenue, very large losses, heavy cash burn, and negative equity with debt). Technicals are also unfavorable with a near-term downtrend and negative MACD, while valuation metrics provide little support due to losses (negative P/E) and no dividend yield.
To see Spark’s full report on RANI stock, click here.
More about Rani Therapeutics Holdings
Rani Therapeutics Holdings, Inc. operates in the biopharmaceutical and drug delivery industry, focusing on developing innovative technologies to orally deliver biologic drugs that are typically administered by injection, targeting patients and healthcare providers seeking less invasive treatment options.
Average Trading Volume: 18,883,506
Technical Sentiment Signal: Hold
Current Market Cap: $164.1M
See more data about RANI stock on TipRanks’ Stock Analysis page.